{"id":"bevacizumab-lumiere","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-15","effect":"Bleeding/hemorrhage"},{"rate":"5-10","effect":"Thromboembolic events"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"},{"rate":"15-20","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and growth, often used in combination with chemotherapy or other targeted agents.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:15.286Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Renal cell carcinoma"},{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT03668054","phase":"PHASE3","title":"Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2017-02-07","conditions":"Age-Related Macular Degeneration","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bevacizumab (Lumiere®)","genericName":"Bevacizumab (Lumiere®)","companyName":"Laboratorio Elea Phoenix S.A.","companyId":"laboratorio-elea-phoenix-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}